Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
The present treatments for lung cancer include surgical resection, radiation, chemotherapy, targeted therapy, and immunotherapy. Despite advances in therapies, the prognosis of lung cancer has not been substantially improved in recent years. Chimeric antigen receptor (CAR)-T cell immunotherapy has a...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.903562/full |
| _version_ | 1818553951188942848 |
|---|---|
| author | Prameela Kandra Rajender Nandigama Bastian Eul Magdalena Huber Sebastian Kobold Sebastian Kobold Werner Seeger Werner Seeger Werner Seeger Friedrich Grimminger Friedrich Grimminger Rajkumar Savai Rajkumar Savai Rajkumar Savai |
| author_facet | Prameela Kandra Rajender Nandigama Bastian Eul Magdalena Huber Sebastian Kobold Sebastian Kobold Werner Seeger Werner Seeger Werner Seeger Friedrich Grimminger Friedrich Grimminger Rajkumar Savai Rajkumar Savai Rajkumar Savai |
| author_sort | Prameela Kandra |
| collection | DOAJ |
| description | The present treatments for lung cancer include surgical resection, radiation, chemotherapy, targeted therapy, and immunotherapy. Despite advances in therapies, the prognosis of lung cancer has not been substantially improved in recent years. Chimeric antigen receptor (CAR)-T cell immunotherapy has attracted growing interest in the treatment of various malignancies. Despite CAR-T cell therapy emerging as a novel potential therapeutic option with promising results in refractory and relapsed leukemia, many challenges limit its therapeutic efficacy in solid tumors including lung cancer. In this landscape, studies have identified several obstacles to the effective use of CAR-T cell therapy including antigen heterogeneity, the immunosuppressive tumor microenvironment, and tumor penetration by CAR-T cells. Here, we review CAR-T cell design; present the results of CAR-T cell therapies in preclinical and clinical studies in lung cancer; describe existing challenges and toxicities; and discuss strategies to improve therapeutic efficacy of CAR-T cells. |
| first_indexed | 2024-12-12T09:32:31Z |
| format | Article |
| id | doaj.art-0cf61627a2184e12bada2c09c02cbad4 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T09:32:31Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-0cf61627a2184e12bada2c09c02cbad42022-12-22T00:28:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.903562903562Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung CancerPrameela Kandra0Rajender Nandigama1Bastian Eul2Magdalena Huber3Sebastian Kobold4Sebastian Kobold5Werner Seeger6Werner Seeger7Werner Seeger8Friedrich Grimminger9Friedrich Grimminger10Rajkumar Savai11Rajkumar Savai12Rajkumar Savai13Department of Biotechnology, Gandhi Institute of Technology and Management (GITAM) Institute of Technology, Gandhi Institute of Technology and Management (GITAM) Deemed to be University, Visakhapatnam, IndiaMax Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research Deutsches Zentrum für Lungenforschung (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, GermanyDepartment of Internal Medicine, Member of the Deutsches Zentrum für Lungenforschung (DZL), Member of Cardio-Pulmonary Institute (CPI), Justus Liebig University, Giessen, GermanyInstitute for Medical Microbiology and Hygiene, Philipps-University Marburg, Marburg, GermanyDivision of Clinical Pharmacology, Department of Medicine IV, Member of the Deutsches Zentrum für Lungenforschung (DZL), University Hospital Munich, Munich, GermanyGerman Cancer Consortium Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner site Munich, Munich, GermanyMax Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research Deutsches Zentrum für Lungenforschung (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, GermanyDepartment of Internal Medicine, Member of the Deutsches Zentrum für Lungenforschung (DZL), Member of Cardio-Pulmonary Institute (CPI), Justus Liebig University, Giessen, GermanyInstitute for Lung Health (ILH), Justus Liebig University, Giessen, GermanyDepartment of Internal Medicine, Member of the Deutsches Zentrum für Lungenforschung (DZL), Member of Cardio-Pulmonary Institute (CPI), Justus Liebig University, Giessen, GermanyInstitute for Lung Health (ILH), Justus Liebig University, Giessen, GermanyMax Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research Deutsches Zentrum für Lungenforschung (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, GermanyDepartment of Internal Medicine, Member of the Deutsches Zentrum für Lungenforschung (DZL), Member of Cardio-Pulmonary Institute (CPI), Justus Liebig University, Giessen, GermanyInstitute for Lung Health (ILH), Justus Liebig University, Giessen, GermanyThe present treatments for lung cancer include surgical resection, radiation, chemotherapy, targeted therapy, and immunotherapy. Despite advances in therapies, the prognosis of lung cancer has not been substantially improved in recent years. Chimeric antigen receptor (CAR)-T cell immunotherapy has attracted growing interest in the treatment of various malignancies. Despite CAR-T cell therapy emerging as a novel potential therapeutic option with promising results in refractory and relapsed leukemia, many challenges limit its therapeutic efficacy in solid tumors including lung cancer. In this landscape, studies have identified several obstacles to the effective use of CAR-T cell therapy including antigen heterogeneity, the immunosuppressive tumor microenvironment, and tumor penetration by CAR-T cells. Here, we review CAR-T cell design; present the results of CAR-T cell therapies in preclinical and clinical studies in lung cancer; describe existing challenges and toxicities; and discuss strategies to improve therapeutic efficacy of CAR-T cells.https://www.frontiersin.org/articles/10.3389/fimmu.2022.903562/fulladaptive therapyCAR-T cellslung cancertumor-associated target antigenstoxicities |
| spellingShingle | Prameela Kandra Rajender Nandigama Bastian Eul Magdalena Huber Sebastian Kobold Sebastian Kobold Werner Seeger Werner Seeger Werner Seeger Friedrich Grimminger Friedrich Grimminger Rajkumar Savai Rajkumar Savai Rajkumar Savai Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer Frontiers in Immunology adaptive therapy CAR-T cells lung cancer tumor-associated target antigens toxicities |
| title | Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer |
| title_full | Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer |
| title_fullStr | Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer |
| title_full_unstemmed | Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer |
| title_short | Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer |
| title_sort | utility and drawbacks of chimeric antigen receptor t cell car t therapy in lung cancer |
| topic | adaptive therapy CAR-T cells lung cancer tumor-associated target antigens toxicities |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.903562/full |
| work_keys_str_mv | AT prameelakandra utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT rajendernandigama utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT bastianeul utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT magdalenahuber utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT sebastiankobold utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT sebastiankobold utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT wernerseeger utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT wernerseeger utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT wernerseeger utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT friedrichgrimminger utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT friedrichgrimminger utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT rajkumarsavai utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT rajkumarsavai utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer AT rajkumarsavai utilityanddrawbacksofchimericantigenreceptortcellcarttherapyinlungcancer |